Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Assets (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Return on Assets for 11 consecutive years, with 0.79% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Assets fell 72.0% year-over-year to 0.79%, compared with a TTM value of 0.79% through Sep 2025, down 72.0%, and an annual FY2024 reading of 0.41%, up 75.0% over the prior year.
  • Return on Assets was 0.79% for Q3 2025 at Avalo Therapeutics, down from 0.35% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.5% in Q1 2025 and bottomed at 1.97% in Q1 2024.
  • Average Return on Assets over 5 years is 0.35%, with a median of 0.18% recorded in 2024.
  • The sharpest move saw Return on Assets crashed -169bps in 2024, then soared 248bps in 2025.
  • Year by year, Return on Assets stood at 0.0% in 2021, then plummeted by -524bps to 0.0% in 2022, then tumbled by -65293bps to 1.26% in 2023, then skyrocketed by 78bps to 0.28% in 2024, then plummeted by -181bps to 0.79% in 2025.
  • Business Quant data shows Return on Assets for AVTX at 0.79% in Q3 2025, 0.35% in Q2 2025, and 0.5% in Q1 2025.